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Increased fetuin-A levels following
treatment with a vitamin D analog
To the Editor: Fetuin-A is one of the several potential
vascular calciﬁcation inhibitors in chronic kidney disease
(CKD) patients; it seems to protect from precipitation of
calcium phosphate under extra-osseous calciﬁcation stress by
organizing a fetuin–mineral complex (FMC).1
Vitamin D has been demonstrated to promote ectopic
calciﬁcations by different mechanisms that also include
fetuin-A exhaustion as a result of FMC formation. This
hypothesis was supported by in vivo evidence in rats fed
with toxic doses of vitamin D,2 which induced ectopic
calciﬁcations and reduction of circulating fetuin-A; however,
this mechanism has never been investigated in humans.
In addition, Matsui et al.1 recently reported a slight decrease
in serum fetuin-A levels and a marked rise in FMC in uremic
rats with very high levels of calcium phosphorus (Ca P)
product.
We studied fetuin-A serum level variations in hemodialysis
patients suffering from secondary hyperparathyroidism,
before and after the administration of a vitamin D analog
(paricalcitol).
We treated 10 consecutive hemodialysis patients with
hyperparathyroidism, who had never received vitamin D
treatment, with i.v. paricalcitol 5mg thrice weekly; we
obtained their sera before the ﬁrst paricalcitol administration
(t0), and after 1 week (t1), 4 weeks (t4), and 8 weeks (t8);
serum levels of fetuin-A (measured using a human fetuin-A
ELISA kit, Epitope Diagnostics, San Diego, CA), high-
sensitivity C-reactive protein (hsCRP), total intact parathy-
roid hormone (PTH), and serum calcium and phosphorus
levels were measured. The results are shown in Figure 1.
Contrary to that reported in rats, we observed, comparing t8
with t0, a progressive and statistically signiﬁcant increase in
serum fetuin-A levels (P¼ 0.01); there was also an increase in
the Ca P product (P¼ 0.42) and a decrease in PTH (P¼ 0.07)
and hsCRP levels (P¼ 0.06), but these changes were not
statistically signiﬁcant. Because it is well known that inﬂamma-
tion, as assessed by hsCRP, may condition fetuin-A synthesis,
we investigated whether changes in fetuin-A correlated with
changes in hsCRP; in our patients there was no signiﬁcant
correlation between these two parameters (r¼0.188,
P¼ 0.60); therefore, the increase in fetuin-A we observed after
paricalcitol treatment did not seem to be accounted for by
changes in the inﬂammatory status of our patients.
The increase in fetuin-A serum levels could be due to
hepatic stimulation of fetuin-A synthesis induced by vitamin
D through its action on the hepatocyte vitamin D receptor.
In agreement with our data, serum levels of 1–25 OH
dihydroxy-vitamin D in untreated CKD patients were found
to correlate with serum fetuin-A levels.3
In conclusion, although vitamin D may elicit vascular
calciﬁcation through an increase in the Ca P product, in
humans it is apparent that it may also activate a counter-
regulatory mechanism that leads to an increased production
of fetuin-A. These data lend further support to the view that
vitamin D may exert pleiotropic effects on different organ
systems, as reviewed by Verstuyf et al.4 in a recent issue of
Kidney International.
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The Author Replies: Manenti et al.1 observed a signiﬁcant
increase in serum fetuin-A levels starting a few weeks after
thrice-a-week paracalcitol treatment of 10 patients on chronic
hemodialysis. The simple consequence could be that such
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Figure 1 | Serum levels of fetuin-A, CaP product,
parathyroid hormone (PTH), and high-sensitivity C-reactive
protein (hsCRP) in the 10 patients studied, before (t0) and
after 1 week (t1), 4 weeks (t4), and 8 weeks (t8) of paricalcitol
treatment.
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increase in fetuin-A, a major inhibitor of (extra-skeletal)
calcium-phosphate deposition, may help to offset the risk of
vitamin D therapy-induced increase in calcium-phosphate
product. However, the observed increase as presented in their
ﬁgure was much delayed, and so it is unlikely to be a direct
effect of the analog treatment. Moreover, the effects of
vitamin D on vascular wall and cardiovascular risks are
extremely complex and involve mostly beneﬁcial effects but
also possible deleterious effects at very high vitamin D levels.2
Ectopic vascular calciﬁcation is a complex phenomenon whereby
mesenchymal cells are redirected to become osteoblast-like
cells that can produce matrix and deposit minerals that then
become calciﬁed vascular lesions.3–5 The vitamin D hormone
and its analogs can indeed induce this (trans)differentiation
in vitro, but in vivo results with either the parent vitamin D
compound6 or vitamin D analogs,3 together with the
beneﬁcial effects of vitamin D analog treatment in chronic
renal failure (CRF) patients7 on overall survival and
cardiovascular events, clearly demonstrate that the vitamin
D effect is much more complex. A poor vitamin D status is
indeed associated with increased prevalence of cardiovascular
risk and events in the general population8 as well as in CRF
patients, so that correction of poor vitamin D status may
improve cardiovascular risks although this requires conﬁrma-
tion by the appropriate randomized controlled trials (RCTs).
The process of vascular mineralization is enhanced by high
phosphate, oxidative stress, vitamin D, and parathyroid
hormone (PTH) (fragments), and bone morphogenic
proteins, but is also inhibited by inhibitors of mineraliza-
tion such as fetuin-A, osteopontin, and matrix gamma-
carboxyglutamate (Gla) protein. Moreover, ﬁbroblast growth
factor (FGF23) and its receptor and co-receptor Klotho are
also very potent regulators of vascular function and even
survival or longevity, but their precise role in the vascular
function or dysfunction needs further clariﬁcation.9,10 There-
fore, the observation of Manenti et al. are just the very brief
start of a series of much needed studies to document the
process of accelerated vascular dysfunction in CRF patients so
as to deﬁne the real culprit and potential natural protectors.
This will allow then to better deﬁne the relative importance of
control of serum calcium, phosphate, and calciotropic
hormones, including FGF23 and Klotho, in the prevention
of cardiovascular and mortality risks. It seems logical that
only a combination of in vitro and in vivo studies in
appropriate animal models and prospective RCTs in
human patients will be able to provide us with the necessary
answers.
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The Authors Reply: We thank Dr Manenti et al.1 for their
interest in our study. Despite no direct evidence showing
the transcriptional regulation of fetuin-A by vitamin D,
paricalcitol might increase fetuin-A production, given that
vitamin D itself has an anti-inflammatory action and that
fetuin-A is a negative acute-phase protein. The lack of
significant correlation between changes in fetuin-A and those
in high-sensitivity C-reactive protein cannot rule out this
possibility, because the number of the patients is so small.
The effect of vitamin D on vascular calciﬁcation appears to be
dependent on the dosage of vitamin D.2 High-dose vitamin D
increases calcium-phosphate product and promotes vascular
calciﬁcation, whereas vitamin D at therapeutic doses can reduce
calciﬁcation by suppressing aortic osteoblastic gene expression.2
Thus, it may not be appropriate to directly compare the result
from rats treated with toxic doses of vitamin D and the one
from humans treated with therapeutic doses.
It is very important to take fetuin-A fractions into consi-
deration when discussing the roles of fetuin-A. Our quoted
paper3 insisted that measuring fetuin-mineral complex (FMC)
rather than fetuin-A is important for evaluating calciﬁcation
stress. Recently, we found that similar FMC could be separated
in the serum of patients with chronic kidney disease (CKD).4
Our results in CKD patients indicated that serum fetuin-A
levels in humans determined by enzyme-linked immunosorbent
assay were the sum of the fetuin-A level bound to calcium and
the free fetuin-A level, and that the former reﬂects ongoing
calciﬁcation stress. From this perspective, further studies seem
to be required to elucidate which type of fetuin-A is increased
by paricalcitol.
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